To make matters worse, the biotech realized that the same duff drug product had been used in a separate ongoing study of ...

After issues with a batch of Jasper Therapeutics' investigational antibody led to "lower" therapeutic effects in several ...

Jasper Therapeutics’ stock has dropped by more than 50% after the company announced it was looking into the impact of a ...

Jasper Therapeutics’ dud drug lot has cost half of the biotech's employees their jobs. | Jasper Therapeutics’ dud drug lot ...

Jasper Therapeutics faced a wave of downgrades Monday after disclosing that a compromised drug product lot disrupted results ...

Shares of Jasper Therapeutics plummeted in premarket trading Monday after the clinical-stage biotechnology company said issues with one lot of its lead drug candidate briquilimab was disrupting ...

First Patient Expected to be Dosed by Year-end 2023; Early Data Expected by Mid-2024 Clinical Study in Chronic Inducible Urticaria Planned to Commence in Early 2024 REDWOOD CITY, Calif., Oct. 09 ...

Investing.com -- Shares of Jasper Therapeutics, Inc. (Nasdaq: JSPR) plummeted over 40% following the release of data from its BEACON study of Briquilimab in Chronic Spontaneous Urticaria (CSU).

Jasper also announced that it expects to report initial data from all cohorts of the BEACON study in CSU during the week of January 6 th, 2025, including the recently added 180mg Q8W dose cohort ...

REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody ...